

FORM 13-501F1
CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS -
PARTICIPATION FEE

MANAGEMENT CERTIFICATION

I, Blake Sing, an officer of the reporting issuer noted below have examined this Form 13-501F1 (the **Form**) being submitted hereunder to the Alberta Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.

"Blake Sing"

Name: Blake Sing
Title: Chief Financial Officer

January 25, 2022

Date:

Reporting Issuer Name: Nurosene Health Inc.

End of date of previous financial year: September 30, 2021

Type of Reporting Issuer: **Class 1 reporting issuer**
 Class 3B reporting issuer

Highest Trading Marketplace: Canadian Securities Exchange (CSE)

Market value of listed or quoted equity securities

Equity Symbol	<u>MEND</u>	
1st Specified Trading Period	<u>07/06/2021</u>	to <u>30/06/2021</u>
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace	\$	<u>2.54</u> (i)
Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period		<u>33,221,078</u> (ii)
Market value of class or series	(i) x (ii) \$	<u>84,381,538</u> (A)

2nd Specified Training Period (dd/mm/yy) 01/07/21 to 30/09/21

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace \$ 1.67 (iii)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period \$ 33,771,611 (iv)

Market value of class or series (iii) x (iv) \$ 56,398,590 (B)

3rd Specified Trading Period (dd/mm/yy) N/A* to N/A*

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace \$ N/A (v)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period N/A (vi)

Market value of class or series (v) x (vi) \$ N/A (C)

4th Specified Trading Period (dd/mm/yy) N/A* to N/A*

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace \$ N/A (vii)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period \$ N/A (viii)

Market value of class or series (vii) x (viii) \$ N/A (D)

5th Specified Trading Period (dd/mm/yy)	<u> N/A* </u>	to	<u> N/A* </u>	
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace			\$ <u> N/A </u>	(ix)
Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period			\$ <u> N/A </u>	(x)
Market value of class or series	(ix) x (x)		\$ <u> N/A </u>	(E)
Average Market Value of Class or Series (Calculate the simple average of the market value of the class or series of security for each applicable specified trading period (i.e. A through E above))			\$ <u> 70,390,064 </u>	(1)

*Nurosene Health Inc. commenced trading on the Canadian Securities Exchange on June 9, 2021 and did not trade on any other stock exchange Canadian or otherwise prior to such date. As such, trading data is only available for Nurosene Health Inc. starting June 9, 2021 through to September 30, 2021 for the previous financial year.

(Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)

Fair value of outstanding debt securities:

(Provide details of how value was determined)		\$	<u>0</u>	(2)
Capitalization for the previous financial year	(1) + (2)	\$	<u>70,390,064</u>	
Participation Fee		\$	<u>3,000</u>	
Late Fee, if applicable		\$	<u>N/A</u>	
Total Fee Payable (Participation Fee plus Late Fee)		\$	<u>3,000</u>	